
# Preliminary Safety and Efficacy Data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine tumors (NETs) (NCT05636618)

# Background

- Neuroendocrine tumors are heterogenous
- >80% overexpress somatostatin receptor 2 (SSTR2)
- Despite the availability of [<sup>177</sup>Lu]Lu-DOTATATE, there remains a high unmet medical need for novel therapies
- [<sup>212</sup>Pb]VMT-α-NET is a modified SSTR2 binding peptide with proprietary chelation technology for <sup>203</sup>Pb, <sup>212</sup>Pb and <sup>212</sup>Bi allowing for optimized delivery and retention of the payload in the tumor microenvironment
- [<sup>212</sup>Pb]VMT-α-NET, a novel targeted alpha radionuclide therapy (TAT) to the SSTR2, is being investigated for safety and efficacy in PRRT-naïve patients with SSTR2-expressing tumors

<b>Trial Parameters</b>	<sup>1</sup> Patient experienced syncope and dose was reduced for cycle 3 and cycle 4 to 2.5 mCi of administered activity Additional notes: (1) 17 patients screened, (2) one patient (102-102) experienced a decline in renal function prior to administration of [ <sup>212</sup> Pb]VMT-α-NET and was not treated.											
Escalation Stage Population	Data cutoff 10/31/24	frated.										
Advanced/Unresectable     or metastatic NETs	Bayesian mTPI-2     design	Primary: DLTs, MFD, RP2D	Treatment Emergent Adverse Events									
<ul> <li>Progressive disease on prior therapy</li> </ul>	Progressive disease on • Dosimetry to be	<ul> <li>Secondary: ORR, DOR, PFS, OS by</li> </ul>	Incidence of TEAEs	[ <sup>212</sup> Pb]-VMT-a-NET 92.5 MBq (2.5 mCi) (N=2)			[ <sup>212</sup> Pb-VMT-a-NET 185 MBq (5.0 mCi) (N=7)			Total (n=9)		
<ul> <li>PRRT naïve</li> <li>FDA approved SSTR2</li> </ul>	screening period by [ <sup>203</sup> Pb]VMT-α-NET		Grade	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 3	Grade 1	Grade 2	Grade 3
PET/CT avid disease	SPECT/CT		<b>AEs by Preferred Term and Grade Reported by Patient</b> [No patients with AE (% of pts treated per cohort)]								pts	
			Most Common (O Fatigue		n ≥ 2 pa 1 (50)	1		ade ≥ 2 2 (28)	1	4 (44)	3 (33)	-

# **Trial Design**



<b>Patient Characteristics (All Treated Patients = 9)</b>						
Age (years)						
Median	63					
Range	37,78					
Sex, n (%)						
Female	4 (44)					
Male	5 (56)					
Race, n (%)						
White	8 (89)					
Asian	1 (11)					
Tumor Type, n (%)						
Pancreatic NET	3 (33)					
Non-pancreatic NET	6 (66)					
Grade, n (%)						
G1	3 (33)					
G2	6 (66)					
Time since diagnosis (months)						
Mean	70					
Median	37					
Range	12, 181					
Number of prior systemic therapies						
Median	1					
Range 0, 2						
Prior systemic therapies (patients with each)						
Somatostatin analogues 7						
Capecitabine, temozolomide 1						
Small molecule (sunitinib, everolimus) 2						

ECOG Performance Status, n (%) 8 (89) 1 (11) Disease at Baseline, median (range) 6.7 (2.9, 8.7) RECIST median sum of target lesions (cm) SUV max 41.5 (18, 162) SUV mean 30 (12, 102) Data cutoff 10/31/24

Washington University in St.Louis


Richard L Wahl<sup>1</sup>, Lowell Anthony<sup>2</sup>, Lilja B Solnes<sup>3</sup>, Samuel H Mehr<sup>4</sup>, Lucia Baratto<sup>5</sup>, Alaa Hanna<sup>5</sup>, Wenjing Yang<sup>5</sup>, Stephen Keefe<sup>5</sup>, Thorvardur R Halfdanarson<sup>6</sup> <sup>1</sup> Washington University, <sup>2</sup> University of Kentucky, <sup>3</sup> Johns Hopkins, <sup>4</sup> Nebraska Cancer Specialists, <sup>4</sup> Virginia Cancer Specialists, <sup>5</sup> Perspective Therapeutics LLC, <sup>6</sup> Mayo Clinic

Patie	atient Disposition & Exposure (all patients as treated)								
ohort	Subject	Subject Status	Weight (kg)	Adm Activity (mCi)	Adm Activity per Weight (µCi/kg)	C1D1	C2D1	C3D1	C4D1
1	103-101	Follow-Up	53	2.5	50.1	$\checkmark$	$\checkmark$	<ul> <li>✓</li> </ul>	✓
1	103-102	Follow-Up	61	2.5	40.8	$\checkmark$	$\checkmark$	✓	✓
2	103-103	Follow-Up	157	5	31.7	$\checkmark$	$\checkmark$	✓	~
2	109-103	Progressive disease	78	5	63.9	$\checkmark$			
2	102-101	Follow-Up	91	5	54.5	$\checkmark$	$\checkmark$	✓	✓
2	103-104	Follow-Up <sup>1</sup>	59	5/2.5	84.5/42.3	$\checkmark$	$\checkmark$	~	✓
2	102-103	Follow-Up	80	5	62.1	$\checkmark$	~	~	scheduled
2	112-101	Follow-up	101	5	49.1	$\checkmark$	$\checkmark$	~	✓
2	103-105	Follow-up	73	5	68.7	$\checkmark$	$\checkmark$	✓	✓


Green line denotes timepoint through which all post-cycle scans are available to the study team.

reated per cohort,				,		- patren			P 20
lost Common (Oco	curring i	n ≥ 2 pa	tients a	nd/or gr	ade ≥ 2				
atigue	1 (50)	1 (50)	-	3 (43)	2 (28)	-	4 (44)	3 (33)	-
lopecia	2 (100)	-	-	4 (57)	-	-	6 (66)	-	-
ymphocyte count									
ecreased	-	1 (50)	-	2 (29)	3 (42)	-	2 (22)	4 (44)	-
ausea	-	1 (50)	-	4 (57)	1 (14)	-	4 (44)	2 (22)	-
naemia	-	2 (100)	-	3 (43)	-	-	3 (33)	2 (22)	-
iarrhoea	2 (100)	-	-	2 (29)	1 (14)	1 (14)	4 (44)	1 (11)	1 (11)
laematocrit ecreased	1 (50)	1 (50)	-	2 (29)	-	-	3 (33)	1 (11)	-
ed blood cell ount decreased	1 (50)	1 (50)	-	2 (29)	-	-	3 (33)	1 (11)	-
/hite blood cell ount decreased	2 (100)	-	-	_	-	-	2 (22)	-	-
bdominal pain	-	-	-	2 (29)	-	-	2 (22)	-	-
laemoglobin ecreased	-	-	-	2 (29)	-	-	2 (22)	-	-
lyperglycaemia	-	-	-	2 (29)	-	-	2 (22)	-	-
lood alkaline hosphatase	-	-	_	2 (29)	-	-	2 (22)	-	-
onstipation	-	-	-	2 (29)	-	-	2 (22)	-	-
laematuria	-	-	-	2 (29)	-	-	2 (22)	-	-
leadache	1 (50)	-	-	1 (14)	-	-	2(22)	-	-
ethargy	1 (50)	-	-	1 (14)	-	-	2(22)	-	-
spartate minotransferase ncr'd	1 (50)	_	_	1 (14)	_	_	2(22)	_	_
izziness	1 (50)	-	_	1 (14)	_	-	2(22)	_	_
resyncope	-	-		-	1 (14)			1 (11)	
yncope	-	-	-	-	-	1 (14)	-	-	1 (11)
mylase increased	-	1 (50)	-	-	-	-	-	1 (11)	-
ypercalcemia	-	1 (50)	-	-	-	-	-	1 (11)	-
leight decreased	-	-	-	-	1 (14)	-	-	1 (11)	-
ote: no renal insufficiency c	or dysphagia v	were observe	d.					Data cuto	off 10/31/24

## **Estimated GFR, Most Recent vs Baseline**




- No DLTs were observed in either cohort
- No grade 4, grade 5 or serious AEs were observed



Data cutoff 10/31/24

Perce Basel 30%
10%
-10%
-30%
-50%

-70%



\* The full sets of scans following cycle 4 are not yet available to the study team for five patients. Notes: Patients had progressive disease prior to enrollment on study, and patient 109-103 experienced progressive disease by unambiguous progression of non-target lesions Data cutoff 10/31/24

# Acknowledgment

Multi Center trial thanking all investigators and the patients who participated. Special thanks to Doctors Vikas Prasad and Nikos Trikalinos, Lauren Sandner and the CCTR (Center for Clinical Theranostics Research) staff from Washington University for their major contributions,

and also Markus Puhlmann, MD, MBA and Ian Marsh, PhD, from Perspective Therapeutics, Inc.

This Trial is sponsored by **PERSPECTIVE** 

Data cutoff 10/31/24

# **Summary of Adverse Events**


- No decline in renal function was observed
- Hematologic AEs were few in number and low grade
- No dysphagia was observed
- No treatment discontinuations due to AE have occurred

# Dosimetry

Predicted Tumor to Kidney Activity of [<sup>212</sup>Pb]VMT-α-NET Over Time (Based on Pre-Treatment [<sup>203</sup>Pb]VMT-α-NĚT SPECT Imaging and Dosimetry Analysis)

Time activity curves for [212Pb]VMT-a-NET are derived from pre-treatment SPECT imaging using 5-7 mCi [203Pb]VMT-a-NET at 1, 4, and 24 hours (n=6). The bold line represents the average across all samples in the dataset for tumors (magenta) and kidney (blue). Measurements of %IA/L in tumors and kidneys has been corrected for partial volume effects. However, SPECT imaging may still underestimate the true tumor to kidney ratio of absorption.


## **Preliminary Response Assessment by RECIST v1.1**





\* The full sets of scans following cycle 4 are not yet available to the study team for five patients. Note: Patient 109-103 experienced progressive disease by unambiguous progression of non-target lesions


## **Kinetics of Treatment Response**
















# **Preliminary Assessment of Disease Control Durability** VMT-a-NET 185 MBg (5.0 mCi) 212Pb-VMT-a-NET 92.5 MBg (2.5 mCi) Death Disease Progression A RECIST v1.1 Response Nonths

Data cutoff 10/31/24

The Safety Monitoring Committee has recommended dose escalation which will be considered with FDA



Please scan for this presentation